Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
Cancer Network,
Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the…
Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the…
INDIANAPOLIS, Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
INDIANAPOLIS, Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the U.S.
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
INDIANAPOLIS, Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.
In this article: ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
NEW YORK--( BUSINESS WIRE )-- Pfizer, Inc. (NYSE: PFE) today announced that the U.S.
As the first-and-only targeted regimen for people with BRAFV600E-mutant metastatic CRC who have received prior therapy…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved (encorafenib) in…
| Spoke Javascript is disabled U.S.
22:27 UTC BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously…
Pfizer Aktionäre handeln die Aktien von Pfizer für einmalig nur 4 Euro HIER GRATIS ANSCHAUEN NEW YORK --(BUSINESS WIRE)-…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib…
BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated…
BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated…
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE: PFE) today announced that the U.S.
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib…
Pfizer Inc. (NYSE: PFE) today announced that the U. Pfizer Inc. ( PFE ) - Get Report today announced that the U.S.
BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated…
U.S. FDA Approves BRAFTOVI ® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAF V600E -Mutant Metastatic…
BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) today announced that the U.S.
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) today announced that the U.S.
The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where…
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE: PFE) today announced that the U.S.
NEW YORK --(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the U.S.
Company Website: http://www.pfizer.com NEW YORK -- (Business Wire) Pfizer Inc. (NYSE: PFE) today announced that the U.S.
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority…
NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) today announced that the U.S.
BEACON CRC is the first and only Phase 3 trial designed to test a BRAF/MEK combo targeted therapy in BRAFV600E-mutant mCRC.
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3…
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI ® (Encorafenib), MEKTOVI ® (Binimetinib) and…
- Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New…
- Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New…
- Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New…
Targeted treatments for cancer have been extending and saving lives for more than 15 years—precision medicine isn't a new idea…